The bcl-2 protein plays an essential role in preventing cell death. Its activity is regulated through association with bcl-2 homologous and nonhomologous proteins and also by serine phosphorylation. We now report that bcl-2 can be proteolytically cleaved towards its N-terminus by a cysteine proteinase present in RL-7 lymphoma cell lysates, yielding a major product of apparent MW 20 kDa, different from the products of bcl-2 cleavage by HIV protease. Moreover, bcl-2 proteins mutated for Asp residues at positions 31 and 34 were efficiently cleaved by RL-7 cell lysates, indicating that this proteolytic activity is distinct from the caspase-3 that cleaves bcl-2 at Asp 34. This bcl-2 cleaving activity is inhibited by E-64 and is therefore distinct from the proteinases of the ICE/Ced-3 family (caspases), whereas reciprocally, ICE (caspase-1) is unable to cleave bcl-2. It is optimally active at pH 5, a feature distinguishing it from calpain, another non-ICE cysteine proteinase which has been associated with apoptosis. This novel bcl-2 cleaving protease, although constitutively present in RL-7 cells and resting peripheral blood lymphocytes (PBL) was upregulated following induction of apoptosis in RL-7 cells or mitogen activation in PBL. The N-terminus of bcl-2 which contains the BH4 domain that binds the kinase Raf-1 and the phosphatase calcineurin is essential for anti-apoptotic activity. Its cleavage might provide a novel post-translational mechanism for regulating bcl-2 function and could amplify ongoing programmed cell death.
Introduction
Programmed cell death results from the complex interplay of a number of positive and negative regulatory factors. [1] [2] [3] Among them, the bcl-2 gene product prevents cells from undergoing apoptosis (programmed cell death) in response to a number of stimuli 4 and plays an indispensable role in the maintenance of the lymphoid system and other tissues, as shown by the study of bcl-2-deficient mice. 5, 6 It is also the prototype of a superfamily of homologous proteins. 7 Its activity is negatively regulated by various mechanisms including heterodimerisation and phosphorylation. 8, 9 Conversely, proteases of the Ced-3/interleukin 1␤-converting enzyme (ICE/caspase-1) family promote apoptosis in both nematodes and mammals. 10, 11 The role of the ICE protein itself in mammals is still ill-defined since ICE-deficient mice have no major defect in apoptosis. 12, 13 Several other proteins homologous to Ced-3/ICE, designated as caspases (cysteine proteinases cleaving after an aspartic acid) to recall their catalytic mechanism, have now been identified and closely associated with apoptosis.
14 One major unknown in the characterization of these proteases remains their substrate. Several proteins including the poly(ADP-ribose) polymerase (PARP), U1-70 kDa protein, lamins, fodrin, and actin are cleaved during apoptosis. [15] [16] [17] [18] [19] In addition, PARP was shown to be a good substrate of CPP32-Yama (caspase-3), a member of the CED-3/ICE family. However, PARP-deficient mice develop normally and display no defect in programmed cell death, suggesting that PARP is not the actual substrate of CPP32, or alternatively that cleavage of PARP by CPP32 is not by itself decisive in ongoing apoptosis. 20 Although caspases have attracted great attention, other cysteine and serine proteases have been implicated in the apoptosis pathway. [21] [22] [23] Thus, the bcl-2-dependent and the protease pathways appear to regulate cell death in an opposite manner. That these two pathways somehow interact has been recently suggested by the isolation of a trimolecular complex formed by CED-9/bcl-2, CED-3 and CED-4 in the nematode 24 and by the discovery of bcl-2 cleavage catalysed by HIV protease 25 and caspase-3. 26 In this study, we identified a cleavage product of human bcl-2 in activated lymphoid cells raising the possibility that a cellular protease could also regulate bcl-2 activity.
Materials and methods

Cell culture
RL-7, a B cell lymphoma line bearing the t(14;18) translocation, kindly provided by ATCC (Rockville, MD, USA) was maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS). Human peripheral blood mononuclear cells were cultured at 1 × 10 6 cells and polyclonally stimulated with the mitogenic lectin phytohemaglutinin at 1 g/ml (Difco, Detroit, MI, USA) for 48 h. They were then expanded at 2 × 10 5 cells/ml with recombinant IL-2 (Roussel-UCLAF, Romainville, France) at 225 IU/ml for 72 h.
Recombinant plasmids expressing human bcl-2␣ and ␤
The bcl-2␣ cDNA in pBluescript-SK was kindly provided by ML Cleary (Stanford University Medical Center, CA, USA). The human bcl-2␤ cDNA was obtained by PCR amplification of retrotranscribed total RNA from RL-7 cells, using sequence specific oligonucleotide primers. The PCR product was subcloned into the Bluescript plasmid and sequenced. Mutations in human bcl-2 pRC-CMV cDNA of the Asp residues at positions 31 and 34 (D31N and D34N) were generated by PCR and confirmed by DNA sequencing. Briefly, a first PCR was performed with the T7 primer and oligonucleotides encompassing the mutated position (D31N, D34N) . A second PCR employed the first PCR product as a megaprimer and the SP6 primer. Sequencing allowed selection of mutated sequences. 27 
In vitro transcription and translation
Bcl-2␣, mutated D31N D34N bcl-2, bcl-2␤, proIL-1␤ pBluescript plasmids (1 g) served as templates for in vitro transcription and translation reactions using the TNT-coupled reticulocyte lysate translation system (Promega, Madison, WI, USA), following the manufacturer's recommendations in the presence of 1 mCi/ml 35 S-methionine (specific activity 1000 Ci/mM, Amersham, Aylesbury, UK).
Cell lysates
Cells were washed and resuspended in lysis buffer containing 10 mM NaCl, 1.5 mM MgCl 2 , 10 mM HEPES pH 7, 0.5% Nonidet-P40 (NP-40) and 0.5% sodium deoxycholate (DOC), for 15 min on ice and then centrifuged for 5 min at 12 000 g to pellet nuclei. Cell lysates from COS cells transfected with ICE cDNA were kindly provided by C Faucheau and A Diu (Roussel-UCLAF).
Proteolysis assay
One l of rabbit reticulocyte lysate containing 35 S-methionine labeled bcl-2␣ or mutated D31N and D34N bcl-2␣ or bcl-2␤ was incubated with 20 l of the cell lysate (corresponding to 5 × 10 6 cells) tested for proteolytic activity. Incubation was carried out at 4°C for 15 min and was terminated by addition of sample buffer and boiling. Samples were migrated on a 12% SDS-polyacrylamide gel and electroblotted to nitrocellulose. Blots were then exposed to X-ray films.
For ICE assay, 1 l of rabbit reticulocyte extract containing proIL-1␤ or bcl-2␣ was incubated with 25 or 50 l of ICE transfected lysate (25 l corresponded to 3-5 × 10 6 cells) for 1 h at 37°C. Samples were then processed as above.
Protease inhibitors
Protease inhibitors were tested at the indicated concentration (Table 1) . They were pre-incubated for 15 min at 4°C with cell (pepstatin, ethyl-trans-epoxysuccininyl-L-leucylamido-3-methyl butane (E64)); in ethanol: (PMSF, N,N,N′N′-tetrakis(2-pyridyl-methyl) ethylenediamine (TPEN)); in methanol: 2,2 dithio-dipyridine (2,2′DTDP) and Ac-Tyr-Val-Ala-Asp-CMK (YVAD-cmk) or in water: (iodoacetamide (IA), benzamidine, aprotinin, soybean trypsin inhibitor (STI), ␣2-macroglobulin, leupeptin, EDTA, EGTA). They were stored at −20°C and then diluted directly in lysis buffer. Divalent metal ions were tested at the indicated concentration ( Table 2) .
Western blot detection of bcl-2 proteins
Cell lysates were migrated on 12% SDS-polyacrylamide gel and transferred onto nitrocellulose. Membranes were blocked with PBS containing 5% non-fat dry milk powder and incubated with mouse anti-human 41-54 bcl-2 monoclonal antibody (Dako, Trappes, France), hamster anti-human bcl-2 monoclonal antibody 6C8 (Pharmingen, CA, USA) or rabbit anti-human 4-21 bcl-2 polyclonal antibody (Santa Cruz, CA, USA), followed by peroxidase-conjugated anti-Ig antibodies of the appropriate species specificity. Detection was carried out with the ECL solution (Amersham).
Induction of apoptosis in RL-7 cells
Apoptosis was induced in RL7 cells by treatment with 10 M and 20 M TPEN. To examine the effect of the protease inhibitor E64, cells were preincubated in the presence or absence of 100 M E64 for 1 h and subsequently treated with TPEN for 8 and 24 h. Apoptosis was assessed by flow cytometric analysis of cells. Apoptotic cells were characterized by a decreased forward scatter and an increased side scatter.
Results and discussion
Bcl-2 N-terminus cleaving activity in cell extracts
In the course of a study of bcl-2 protein expression in activated human lymphoid cells, we identified two molecular species immunoreactive with an anti-bcl-2 monoclonal anti- 2 5 + ZnSO 4 1 + MgCl 2 5 − Heavy metals were tested at the indicated concentrations following the same protocol as in Table 1 .
body by Western blotting. The larger species had an apparent MW of 25 kDa, corresponding to the bcl-2␣ isoform. The smaller fragment of MW 20 kDa did not correspond to any previously described bcl-2-related peptide. In particular, its MW was less than that of the bcl-2␤ isoform which is translated from an alternatively spliced messenger RNA and differs from bcl-2␣ at its C-terminal end (Figure 1a, lane 1) . A bcl-2 cross-immunoreactive peptide of similar MW was also found in extracts of RL-7 lymphoma cells ( Figure 1a, lane 2) . To refine the mapping of the cleavage site, RL-7 cell lysates were probed by immunoblotting with anti-bcl-2 antibodies directed against linear epitopes corresponding to peptides 4-21 and 41-54 of bcl-2, respectively. As seen in Figure 1b , the larger protein was recognized by both antibodies, whereas the smaller was labeled only by anti-41-54 bcl-2 monoclonal antibody. The 6C8 antibody, another monoclonal antibody obtained by immunization with the complete bcl-2 protein, also recognized both products (data not shown). Cleavage of bcl-2␣ and bcl-2␤ proteins by RL-7 lysate. 35 S-labeled bcl-2␣ (lanes 1-3) and ␤ proteins (lanes 4-6) synthesized by in vitro transcription-translation were incubated in the absence (lanes 1, 4) or presence of RL-7 lysates (lanes 2, 3, 5, 6) at 4°C for 15 min. Cleavage was fully prevented by preincubation with the protease inhibitor leupeptin (lanes 3, 6).
These results suggested that the smaller species represented a cleavage product of bcl-2 and that the proteolytic site was located toward the N-terminus, likely within the first 50 residues. To investigate this hypothesis, 35 S-methionine-labeled bcl-2␣ protein was obtained by in vitro translation with rabbit reticulocyte lysate and was incubated with extracts of RL-7 cells. As seen in Figure 2 (lane 2), a smaller fragment of size similar to that of the fragment generated in vivo was observed. The in vitro translated bcl-2␤ peptide underwent a similar decrease in its apparent MW, indicating that the cleavage site was localized towards the N-terminal end which is shared by bcl-2␣ and bcl-2␤ (lane 5). This likely position of the cleavage site, as deduced by the cleavage product size, was thus very different from that of HIV protease, between Phe 112 and Ala 113.
Cysteine proteinases, notably including caspases, cleave their substrate at Aspartate residues. The N-terminus of human bcl-2 contains two such residues at positions 31 and 34 which are potential sites of cleavage. Mutations of either or both of these residues in human bcl-2 were therefore generated.
35
Smethionine-labeled mutated proteins were synthesized and treated with RL-7 lysates. No inhibition of cleavage was shown with single or double mutants (Figure 3 ).
Figure 3
Bcl-2 is not cleaved by RL-7 cell lysates at Asp 31 and 34.
35 S-labeled in vitro translated bcl-2 proteins, wild type or D31N and D34N mutants, were incubated in the presence of RL-7 lysates at 4°C for 15 min.
Characterization of the bcl-2 cleaving activity
To characterize the bcl-2 proteolytic activity, the effect of protease inhibitors was tested. RL-7 lysates were incubated with different protease inhibitors and the 35 S-methionine-labeled bcl-2 substrate was added. Leupeptin, a common inhibitor of cysteine and serine proteases, prevented cleavage of bcl-2 ( Figure 2, lanes 3, 6 and Figure 4a, lane 4) . No inhibition was observed with serine protease inhibitors, including PMSF (Figure 4a, lane 2) , benzamidine, aprotinin, STI and ␣2-macroglobulin (Table 1) .
In contrast, E64, a classical inhibitor of cysteine proteases, 25 completely prevented bcl-2 cleavage at a concentration of 100 M (Figure 4a, lane 3) . Other cysteine protease inhibitors including 2,2′DTDP and IA (lane 5) also efficiently inhibited bcl-2 proteolysis. Pepstatin, an inhibitor of aspartyl proteases, did not prevent cleavage and actually seemed to increase the amount of cleaved product (Figure 4b, lane 2) . Controls with solvents alone indicated the specificity of the inhibition (lanes 7, 8, 9). Divalent cations also influenced this reaction which was completely blocked by EDTA (Figure 4b, lane 6 ) and by EGTA (data not shown). Proteolysis of bcl-2 was also totally inhibited by ZnSO 4 (lane 5), Co(NO 3 ) 2 , HgCl 2 , CuSO 4 and Ni(AcO) 2 , whereas MnSO 4 and MgCl 2 had no effect ( Table 2) .
The optimal pH of the cleavage reaction was found to be slightly acidic at 5-5.5 ( Figure 5 ), although cleavage was also seen at neutral pH in RL-7 lysates, thus showing a broad range of pH activity (not shown). This optimal acidic pH of activity is a feature distinctive from neutral calpain, another cysteine proteinase which was also associated with apoptosis. 28 Altogether, these data suggested that bcl-2 was cleaved by an acidic cysteine proteinase with classical properties as suggested by E64 inhibitory capacity, and therefore distinct from the members of the Ced3/ICE family. 29 That bcl-2 cleaving activity was distinct from ICE was directly tested (Figure 6a ). Lysates from COS cells expressing an ICE cDNA did not affect bcl-2 whereas proIL-1␤ was almost completely cleaved. In addition, YVAD.cmk, a specific inhibitor of ICE, completely prevented proteolysis of proIL-1␤ by ICE-transfected COS cell lysate whereas a 100-fold greater concentration was required to prevent bcl-2 cleavage by RL-7 extracts (Figure 6b ). In this inhibition experiment, lysate concentrations were adjusted to yield approximately 50% cleavage of ICE on proIL-1␤ and bcl-2 substrates.
Upregulation of bcl-2 cleavage activity in apoptotic RL-7 cells
To determine whether endogenous bcl-2 was cleaved in vivo after exposure to an apoptotic stimulus, RL-7 cells were treated for 8 and 24 h with TPEN, a chelator of Zn which is also a potent inducer of apoptosis. An increased cleavage of bcl-2 was found in apoptotic extracts (Figure 7 ). This result suggests that the protease was upregulated during apoptosis, in addition to being constitutively present in RL-7 cells.
Preincubation of cells with E64 inhibitor prior to TPEN addition did not prevent onset of apoptosis (not shown). This indicated that bcl-2 cleavage by this protease was not crucial for onset of apoptosis and that bcl-2 could represent a downstream substrate in the apoptotic pathway.
In conclusion, taken together, our data show the existence of a novel cysteine proteinase capable of cleaving bcl-2 that
Figure 5
Bcl-2 is optimally cleaved at pH 5. RL-7 cell lysates were adjusted at the indicated pH and probed for bcl-2 expression.
Figure 6
Bcl-2 cleaving activity is distinct from ICE. (a) proIL-␤ (lanes 1-3) and bcl-2␣ (lanes 4-6) were produced by in vitro transcription-translation and were incubated alone (lanes 1, 6) or in the presence of 25 l (lanes 2, 4) or 50 l (lanes 3, 5) of ICE-transfected COS cell lysates. Samples were migrated on 12% SDS-PAGE and autoradiographed. (b) Differential effect of ICE inhibitor YVAD-cmk on cleavage of proIL-␤ (lane 2) and bcl-2 (lanes 4-6) by ICE-transfected COS lysates (lanes 2, 3) or RL-7 cell lysates (lanes 4-7).
Figure 7
Upregulation of bcl-2 of cleavage activity in apoptotic RL-7 cells. Cleavage of endogenous bcl-2 by RL-7 cell lysates after treatment with the apoptotic stimulus TPEN at 10 and 20 M concentrations, respectively, during 8 h (lanes 2, 3) . Untreated RL-7 cell lysates (lane 1) were taken as control.
does not belong to the Ced-3/ICE family, as revealed by the inhibitory effect of E64. 29 From the apparent MW of the cleavage products, this protease is different from the recently described bcl-2 cleaving activity associated with HIV protease. 25 It is also unambiguously distinct from caspase-3 due to differing enzymatic properties and unaffected cleavage of bcl-2 substrates that are mutated for Asp 31 or Asp 34. 26 Both caspase 3 and the novel protease described here remove the N-terminus of the bcl-2 protein, which contains the BH-4 domain and is essential to promote cell survival. This results in inactivation of bcl-2. 31 The BH4 domain is found in all antiapoptotic protein members of the bcl-2 superfamily and is absent from most of its pro-apoptotic members. It is required for binding and targeting the kinase Raf-1 to mitochondria. It also binds the Ca + -dependent protein phosphatase calcineurin and causes its translocation to cellular membrane, preventing its interaction with NF-AT. 30, 32 In addition to its docking activity, bcl-2 also functions as an ion channel, notably controlling mitochondrial permeability transition and the release of apoptogenic protease activators from mitochondria. Activated proteases might in turn cleave bcl-2. 33 It would be of interest to determine if other members of the bcl-2 family undergo the same type of cleavage.
The failure to prevent apoptosis by preincubation with E64 indicates that bcl-2 cleavage is not essential for onset or undergoing apoptosis. This has been shown for several other proteolytic activities associated with apoptosis as well as for DNA degradation. 23, 34 Rather, this post-translational modification of bcl-2 would amplify the cell death program, perhaps in an irreversible manner. It might therefore provide an additional means of regulating bcl-2 function besides association with other homologous or nonhomologous proteins 8 and inactivation by phosphorylation. 
